These findings provide evidence that the combination of REG + aPD1 leads to a sustained polarization of TAMs towards the M1 phenotype, which together with an increased CD8+/Treg cell ratio may contribute to the synergistic anti-tumor activity of REG + aPD1 compared with REG monotherapy. The gene discussed is REG1A; the disease is neoplasm.